Aurobindo Gains on FDA Nod; Sun Pharma, Wockhardt Trade Mixed

Aurobindo Pharma shares jumped as much as 3.3 per cent to hit intraday high of Rs 779.70 after the company got approval from the US Food and Drug Administration (USFDA) to manufacture and market generic version of Eli Lilly's Evista tablets used for treatment of osteoporosis in post-menopausal women.

The product has an estimated market size of $404 million for the 12 months ended June 2015, the Aurobindo Pharma said, citing IMS data.

Separately, Sun Pharma and Wockhardt individually initiated voluntary recall of specific drugs from the US market.

Sun Pharma initiated voluntary recall of multiple lots of Bupropion Hydrochloride Extended-A-release Tablets USP (SR), 200 mg, 60-count bottle, from the 

US market for "failed dissolution specification", while Wockhardt started recalling its Lisinopril Tablets USP, 5 mg and 20 mg.

Sun Pharma ended 1.4 per cent higher while Wockhardt ended 0.6 per cent lower. Aurobindo Pharma also ended 0.1 per cent lower.

(With PTI inputs)